Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab-rwlc) won U.S. Food and Drug Administration approval for the first-line treatment of patients with advanced non-small cell lung cancer whose tumors have high PD-L1 expression.
https://www.pharmalive.com/wp-content/uploads/2021/02/Regeneron-and-Sanofi-Collab-Picks-Up-Third-FDA-Drug-Approval-BioSpace-2-23-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-02-23 11:36:142021-02-23 14:24:09Regeneron and Sanofi Collaboration Receives Third FDA Drug Approval